Madrigal Pharmaceuticals (MDGL) Stock: Buy, Sell, or Hold?
MDGL - Madrigal Pharmaceuticals, Inc. Common Stock
$534.49
1.37 (0.26%)
â˛
5d:
-1.5%
30d:
-0.32%
90d:
+12.7%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When MDGL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: MDGL is fairly priced but lacks strong directional signals. At -16.1% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: MDGL is fairly priced but lacks strong directional signals. At -16.1% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$337.16
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$209.35
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: MDGL is currently trading at $534.49, which is considered slightly high relative to its 30-day fair value range of $510.20 to $541.47. From a valuation perspective, the stock is trading at a discount (Forward PE: 55.5) compared to its historical average (93.9). Remarkably, the market is currently pricing in an annual earnings decline of 16.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, MDGL is in a uptrend. The price is currently testing key support at $519.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $678.06 (+26.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MDGL is in a uptrend. The price is currently testing key support at $519.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $678.06 (+26.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$510.20 -
$541.47
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
71.9%
Protect Your Profits
Holding MDGL? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 26.9% below Wall St target ($678.06)
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$510.20 -
$541.47
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$32.55
(6.1%)
Support & Resistance Levels
Support Level
$519.10
Resistance Level
$552.08
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
55.53
Wall Street Target
$678.06
(+26.9%)
Revenue Growth (YoY)
71.2%
Profit Margin
-25.3%
Valuation Discount vs History
-16.1% cheaper
PE vs Historical
55.5 vs 93.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-16.1%
(market-implied from PE analysis)
1-Year Target
$481.04
(-10%)
2-Year Target
$432.94
(-19%)
3-Year Target
$389.64
(-27%)
3-Yr Target (if PE normalizes)
(PE: 56â94)
$658.86
(+23%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 55.5 to 93.9
Stabilization Target:
$903.79
(+69.1%)
PE Expansion Potential:
+69.1%
Share & Embed Analysis
Last updated: September 11, 2026 11:26 PM ET
Data refreshes hourly during market hours. Next update: 12:26 AM
Data refreshes hourly during market hours. Next update: 12:26 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDGL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$570 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$315 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
Advanced MDGL Option Strategies
Professional options setups generated by AI based on today's MDGL price and gamma walls.
